title: [Congenital toxoplasmosis: randomised comparison of strategies for             retinochoroiditis prevention].
abstract: In France, children with confirmed congenital toxoplasmosis receive a treatment for a           period of 12 to 24 months. Such prolonged treatment may generate potentially severe risks,           in particular hematologic and cutaneous. Our objective is to compare the effectiveness of           two therapeutic strategies on the prevention of retinochoroiditis by a randomized,           non-inferiority, open-label, parallel study including 486 children, 3 to 6 months of age           with a non-severe form of congenital toxoplasmosis. Following randomization,           pyrimethamine-sulphonamide treatment is initiated for a period of three months, followed           by a treatment with Fansidar(®) for 9 months, or therapeutic abstention.           Follow-up visits during a two-year period will include an examination of the eye, a blood           test, and questionnaires to evaluate the children's quality of life and their parents'           anxiety. Confirming the non-inferiority of the effectiveness of a short-term treatment           will improve the quality of life of parents and children.
authors.affiliation: Service de Parasitologie et de Pathologie Exotique Hôpital de la Croix-Rousse, Lyon, France. martine.wallon@chu-lyon.fr
authors.forename: Martine
authors.initials: M
authors.lastname: Wallon
authors.forename: François
authors.initials: F
authors.lastname: Kieffer
authors.forename: Christine
authors.initials: C
authors.lastname: Binquet
authors.forename: Philippe
authors.initials: P
authors.lastname: Thulliez
authors.forename: Patricia
authors.initials: P
authors.lastname: Garcia-Méric
authors.forename: Pascal
authors.initials: P
authors.lastname: Dureau
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Franck
authors.forename: François
authors.initials: F
authors.lastname: Peyron
authors.forename: Alain
authors.initials: A
authors.lastname: Bonnin
authors.forename: Isabelle
authors.initials: I
authors.lastname: Villena
authors.forename: Claire
authors.initials: C
authors.lastname: Bonithon-Kopp
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Gouyon
authors.forename: Sandrine
authors.initials: S
authors.lastname: Masson
authors.forename: Alexandrin
authors.initials: A
authors.lastname: Félin
authors.forename: Catherine
authors.initials: C
authors.lastname: Cornu
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D002833:Choroiditis / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D011739:Pyrimethamine / Q000627:therapeutic use; D011788:Quality of Life; D013449:Sulfonamides / Q000627:therapeutic use; D014125:Toxoplasmosis, Congenital / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D000962:Antimalarials; D013449:Sulfonamides; D011739:Pyrimethamine